{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:53:16Z","timestamp":1791337996533,"version":"4.3.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T00:00:00Z","timestamp":1442793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T00:00:00Z","timestamp":1442793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00280-015-2861-1","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T06:21:46Z","timestamp":1442816506000},"page":"1113-1132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":211,"title":["Targeted therapy in cancer"],"prefix":"10.1007","volume":"76","author":[{"given":"Apostolia-Maria","family":"Tsimberidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,21]]},"reference":[{"issue":"22","key":"2861_CR1","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","volume":"18","author":"AM Tsimberidou","year":"2012","unstructured":"Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R (2012) Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res Off J Am Assoc Cancer Res 18(22):6373\u20136383. doi: 10.1158\/1078-0432.CCR-12-1627","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"33","key":"2861_CR2","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","volume":"28","author":"DD Von Hoff","year":"2010","unstructured":"Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R (2010) Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol Off J Am Soc Clin Oncol 28(33):4877\u20134883. doi: 10.1200\/JCO.2009.26.5983","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2861_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14694\/EdBook_AM.2014.34.61","volume":"34","author":"AM Tsimberidou","year":"2014","unstructured":"Tsimberidou AM, Eggermont AM, Schilsky RL (2014) Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book 34:61\u201369. doi: 10.14694\/EdBook_AM.2014.34.6100114000061","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"2861_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","volume":"19","author":"WE Tidyman","year":"2009","unstructured":"Tidyman WE, Rauen KA (2009) The RASopathies: developmental syndromes of Ras\/MAPK pathway dysregulation. Curr Opin Genet Dev 19(3):230\u2013236. doi: 10.1016\/j.gde.2009.04.001","journal-title":"Curr Opin Genet Dev"},{"issue":"22","key":"2861_CR5","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ (2007) Targeting the Raf\u2013MEK\u2013ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26(22):3291\u20133310. doi: 10.1038\/sj.onc.1210422","journal-title":"Oncogene"},{"issue":"14","key":"2861_CR6","first-page":"3883","volume":"63","author":"J Dong","year":"2003","unstructured":"Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63(14):3883\u20133885","journal-title":"Cancer Res"},{"issue":"4","key":"2861_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.cmr.0000222600.73179.f3","volume":"16","author":"JN Poynter","year":"2006","unstructured":"Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16(4):267\u2013273. doi: 10.1097\/01.cmr.0000222600.73179.f3","journal-title":"Melanoma Res"},{"issue":"12","key":"2861_CR8","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","volume":"19","author":"KG Griewank","year":"2013","unstructured":"Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Susskind D, Hillen U, Speicher MR, Woodman SE, Steuhl KP, Schadendorf D (2013) Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res Off J Am Assoc Cancer Res 19(12):3143\u20133152. doi: 10.1158\/1078-0432.CCR-13-0163","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"26","key":"2861_CR9","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","volume":"24","author":"JA Curtin","year":"2006","unstructured":"Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol Off J Am Soc Clin Oncol 24(26):4340\u20134346. doi: 10.1200\/JCO.2006.06.2984","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"2861_CR10","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","volume":"363","author":"CD Van Raamsdonk","year":"2010","unstructured":"Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O\u2019Brien J, Bastian BC (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23):2191\u20132199. doi: 10.1056\/NEJMoa1000584","journal-title":"N Engl J Med"},{"issue":"26","key":"2861_CR11","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O\u2019Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507\u20132516. doi: 10.1056\/NEJMoa1103782","journal-title":"N Engl J Med"},{"issue":"9839","key":"2861_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358\u2013365. doi: 10.1016\/S0140-6736(12)60868-X","journal-title":"Lancet"},{"issue":"25","key":"2861_CR13","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMc1111672","volume":"365","author":"NM Rochet","year":"2011","unstructured":"Rochet NM, Kottschade LA, Markovic SN (2011) Vemurafenib for melanoma metastases to the brain. N Engl J Med 365(25):2439\u20132441. doi: 10.1056\/NEJMc1111672","journal-title":"N Engl J Med"},{"issue":"11","key":"2861_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087\u20131095. doi: 10.1016\/S1470-2045(12)70431-X","journal-title":"Lancet Oncol"},{"issue":"2","key":"2861_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D, Group MS (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107\u2013114. doi: 10.1056\/NEJMoa1203421","journal-title":"N Engl J Med"},{"issue":"18","key":"2861_CR16","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694\u20131703. doi: 10.1056\/NEJMoa1210093","journal-title":"N Engl J Med"},{"issue":"8","key":"2861_CR17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1470-2045(13)70237-7","volume":"14","author":"C Robert","year":"2013","unstructured":"Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR (2013) Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 14(8):733\u2013740. doi: 10.1016\/S1470-2045(13)70237-7","journal-title":"Lancet Oncol"},{"issue":"31","key":"2861_CR18","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1200\/JCO.2010.31.8162","volume":"29","author":"W Brugger","year":"2011","unstructured":"Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F (2011) Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 29(31):4113\u20134120. doi: 10.1200\/JCO.2010.31.8162","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"2861_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","volume":"14","author":"PA Janne","year":"2013","unstructured":"Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crino L (2013) Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14(1):38\u201347. doi: 10.1016\/S1470-2045(12)70489-8","journal-title":"Lancet Oncol"},{"key":"2861_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv072","author":"G Blumenschein Jr","year":"2015","unstructured":"Blumenschein G Jr, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Janne PA (2015) A randomized phase 2 study of the MEK1\/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small cell lung cancer (NSCLC). Ann Oncol. doi: 10.1093\/annonc\/mdv072","journal-title":"Ann Oncol"},{"issue":"5573","key":"2861_CR21","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655\u20131657. doi: 10.1126\/science.296.5573.1655","journal-title":"Science"},{"issue":"7","key":"2861_CR22","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1073\/pnas.0712169105","volume":"105","author":"L Zhao","year":"2008","unstructured":"Zhao L, Vogt PK (2008) Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 105(7):2652\u20132657. doi: 10.1073\/pnas.0712169105","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5351","key":"2861_CR23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1126\/science.279.5351.710","volume":"279","author":"L Stephens","year":"1998","unstructured":"Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT (1998) Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279(5351):710\u2013714","journal-title":"Science"},{"issue":"13","key":"2861_CR24","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.4161\/cbt.21788","volume":"13","author":"JS Kim","year":"2012","unstructured":"Kim JS, Yun HS, Um HD, Park JK, Lee KH, Kang CM, Lee SJ, Hwang SG (2012) Identification of inositol polyphosphate 4-phosphatase type II as a novel tumor resistance biomarker in human laryngeal cancer HEp-2 cells. Cancer Biol Ther 13(13):1307\u20131318. doi: 10.4161\/cbt.21788","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"2861_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","volume":"110","author":"K Hara","year":"2002","unstructured":"Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110(2):177\u2013189","journal-title":"Cell"},{"issue":"1","key":"2861_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57\u201370","journal-title":"Cell"},{"issue":"6","key":"2861_CR27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529. doi: 10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"key":"2861_CR28","doi-asserted-by":"publisher","unstructured":"Wagner AJ, Von Hoff DH, Lorusso PM, Tibes R, Mazina KE, Ware JA et al (2009) A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. In: ASCO annual meeting proceedings. doi: 10.1200\/JCO.2008.18.5918","DOI":"10.1200\/JCO.2008.18.5918"},{"key":"2861_CR29","doi-asserted-by":"crossref","unstructured":"Moreno Garcia V, Baird RD, Shah KJ, Basu B, Tunariu N, Blanco M et al (2011) A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. In: ASCO annual meeting proceedings, vol 29, p 3021","DOI":"10.1200\/jco.2011.29.15_suppl.3021"},{"key":"2861_CR30","doi-asserted-by":"publisher","unstructured":"Von Hoff DD, LoRusso P, Demetri GD, Weiss GJ, Shapiro G, Ramanathan RK et al (2011) A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. In: ASCO annual meeting proceedings, vol 29, p 3052. doi: 10.1200\/JCO.2011.36.5742","DOI":"10.1200\/JCO.2011.36.5742"},{"issue":"3","key":"2861_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","volume":"30","author":"JC Bendell","year":"2012","unstructured":"Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 30(3):282\u2013290. doi: 10.1200\/JCO.2011.36.1360","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2861_CR32","unstructured":"Arkenau H-T, Jones SF, Kurkjian C, Infante JR, Pant S, Burris HA et al (2012) The PI3K\/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors. In: ASCO annual meeting proceedings, vol 30, abstr. 3097"},{"key":"2861_CR33","doi-asserted-by":"publisher","unstructured":"Krop IE, Saura C, Ahnert JR, Becerra C, Britten CD, Isakoff SJ et al (2012) A phase I\/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. In: ASCO annual meeting proceedings, vol 30, abstr. 508. doi: 10.1200\/JCO.2011.40.5902","DOI":"10.1200\/JCO.2011.40.5902"},{"issue":"5","key":"2861_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19(5):575\u2013586. doi: 10.1016\/j.ccr.2011.04.008","journal-title":"Cancer Cell"},{"issue":"4","key":"2861_CR35","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/sj.bjc.6605554","volume":"102","author":"AH Reid","year":"2010","unstructured":"Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS, Transatlantic Prostate G (2010) Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102(4):678\u2013684. doi: 10.1038\/sj.bjc.6605554","journal-title":"Br J Cancer"},{"issue":"5","key":"2861_CR36","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","volume":"13","author":"C Fritsch","year":"2014","unstructured":"Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR (2014) Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther 13(5):1117\u20131129. doi: 10.1158\/1535-7163.MCT-13-0865","journal-title":"Mol Cancer Ther"},{"key":"2861_CR37","doi-asserted-by":"crossref","unstructured":"Juric AAG, Burris HA, Juric D et al (2012) Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC). Cancer Res. 72(24 supplement):P6-10-07","DOI":"10.1158\/0008-5472.SABCS12-P6-10-07"},{"issue":"1","key":"2861_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/0008-5472.CAN-11-1515","volume":"72","author":"KP Hoeflich","year":"2012","unstructured":"Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Engst S, Johnston S, Friedman LS, Belvin M (2012) Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 72(1):210\u2013219. doi: 10.1158\/0008-5472.CAN-11-1515","journal-title":"Cancer Res"},{"issue":"4","key":"2861_CR39","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","volume":"21","author":"PL Bedard","year":"2015","unstructured":"Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Perez-Garcia J, Stathis A, Britten CD, Le N, Carter K, Demanse D, Csonka D, Peters M, Zubel A, Nauwelaerts H, Sessa C (2015) A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1\/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res 21(4):730\u2013738. doi: 10.1158\/1078-0432.CCR-14-1814","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"11","key":"2861_CR40","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"F Ciardiello","year":"2008","unstructured":"Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358(11):1160\u20131174. doi: 10.1056\/NEJMra0707704","journal-title":"N Engl J Med"},{"issue":"9496","key":"2861_CR41","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","volume":"366","author":"N Thatcher","year":"2005","unstructured":"Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496):1527\u20131537. doi: 10.1016\/S0140-6736(05)67625-8","journal-title":"Lancet"},{"issue":"2","key":"2861_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, National Cancer Instituteof Canada Clinical Trials G (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123\u2013132. doi: 10.1056\/NEJMoa050753","journal-title":"N Engl J Med"},{"issue":"21","key":"2861_CR43","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129\u20132139. doi: 10.1056\/NEJMoa040938NEJMoa040938","journal-title":"N Engl J Med"},{"issue":"5676","key":"2861_CR44","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497\u20131500. doi: 10.1126\/science.1099314","journal-title":"Science"},{"issue":"15","key":"2861_CR45","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","volume":"26","author":"LV Sequist","year":"2008","unstructured":"Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26(15):2442\u20132449. doi: 10.1200\/JCO.2007.14.8494","journal-title":"J Clin Oncol"},{"issue":"16","key":"2861_CR46","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.2006.09.4300","volume":"25","author":"F Cappuzzo","year":"2007","unstructured":"Cappuzzo F, Ligorio C, Janne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L, Varella-Garcia M (2007) Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive\/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25(16):2248\u20132255. doi: 10.1200\/JCO.2006.09.4300","journal-title":"J Clin Oncol"},{"issue":"10","key":"2861_CR47","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947\u2013957. doi: 10.1056\/NEJMoa0810699","journal-title":"N Engl J Med"},{"issue":"2","key":"2861_CR48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology G (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121\u2013128. doi: 10.1016\/S1470-2045(09)70364-X","journal-title":"Lancet Oncol"},{"issue":"25","key":"2861_CR49","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study G (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380\u20132388. doi: 10.1056\/NEJMoa0909530","journal-title":"N Engl J Med"},{"issue":"8","key":"2861_CR50","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735\u2013742. doi: 10.1016\/S1470-2045(11)70184-X","journal-title":"Lancet Oncol"},{"issue":"3","key":"2861_CR51","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L, Spanish Lung Cancer Group in collaboration with Groupe Francais de P-C, Associazione Italiana Oncologia T (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239\u2013246. doi: 10.1016\/S1470-2045(11)70393-X","journal-title":"Lancet Oncol"},{"issue":"6","key":"2861_CR52","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","volume":"11","author":"F Cappuzzo","year":"2010","unstructured":"Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, Klingelschmitt G, Klughammer B, Giaccone G, Investigators S (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11(6):521\u2013529. doi: 10.1016\/S1470-2045(10)70112-1","journal-title":"Lancet Oncol"},{"issue":"10","key":"2861_CR53","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S1470-2045(13)70310-3","volume":"14","author":"MC Garassino","year":"2013","unstructured":"Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S, Trialists T (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14(10):981\u2013988. doi: 10.1016\/S1470-2045(13)70310-3","journal-title":"Lancet Oncol"},{"key":"2861_CR54","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ijrobp.2014.08.025","volume":"90","author":"NK Altorki","year":"2014","unstructured":"Altorki NK, O\u2019brien MER, Eberhardt WEE, Richardson FC, Wang J, Foley MA, Horan JD, Shepherd FA, Kelly K (2014) Adjuvant erlotinib (E) versus placebo (P) for completely resected stage IB-IIIA EGFR-positive (IHC\/FISH) non-small cell lung cancer (NSCLC): RADIANT results. Int J Radiat Oncol 90:S2\u2013S3","journal-title":"Int J Radiat Oncol"},{"issue":"15S","key":"2861_CR55","first-page":"7520","volume":"27","author":"F Richardson","year":"2009","unstructured":"Richardson F, Richardson K, Sennello G, Young D, Orlov S, Papai-Szekely Z, Keshavjee S, Kim J, Cerfolio R, Shepherd FA (2009) Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT). ASCO Meet Abstr 27(15S):7520","journal-title":"ASCO Meet Abstr"},{"key":"2861_CR56","doi-asserted-by":"crossref","unstructured":"Neal JW, Pennell NA, Govindan R, Lanuti M, Rosovsky RPG, Heist RS, Shaw AT, Temel JS, Muzikansky A, Janne PA, Lynch TJ, Azzoli CG, Sequist LV (2012) The SELECT study: a multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). In: ASCO meeting abstracts, vol 30 (15_suppl), p 7010","DOI":"10.1200\/jco.2012.30.15_suppl.7010"},{"issue":"27","key":"2861_CR57","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N, O\u2019Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327\u20133334. doi: 10.1200\/JCO.2012.44.2806","journal-title":"J Clin Oncol"},{"issue":"75","key":"2861_CR58","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26. doi: 10.1126\/scitranslmed.3002003","journal-title":"Sci Transl Med"},{"issue":"6","key":"2861_CR59","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2009.21.9618","volume":"28","author":"TJ Lynch","year":"2010","unstructured":"Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D (2010) Cetuximab and first-line taxane\/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28(6):911\u2013917. doi: 10.1200\/JCO.2009.21.9618","journal-title":"J Clin Oncol"},{"issue":"9674","key":"2861_CR60","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","volume":"373","author":"R Pirker","year":"2009","unstructured":"Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O\u2019Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U, Team FS (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373(9674):1525\u20131531. doi: 10.1016\/S0140-6736(09)60569-9","journal-title":"Lancet"},{"issue":"4","key":"2861_CR61","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337\u2013345. doi: 10.1056\/NEJMoa033025","journal-title":"N Engl J Med"},{"issue":"20","key":"2861_CR62","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20):2040\u20132048. doi: 10.1056\/NEJMoa071834","journal-title":"N Engl J Med"},{"issue":"6","key":"2861_CR63","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.ejca.2012.11.018","volume":"49","author":"L Licitra","year":"2013","unstructured":"Licitra L, Storkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F (2013) Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer 49(6):1161\u20131168. doi: 10.1016\/j.ejca.2012.11.018","journal-title":"Eur J Cancer"},{"issue":"5","key":"2861_CR64","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5):663\u2013671. doi: 10.1200\/JCO.2008.20.8397","journal-title":"J Clin Oncol"},{"issue":"7","key":"2861_CR65","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","volume":"25","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25(7):1346\u20131355. doi: 10.1093\/annonc\/mdu141","journal-title":"Ann Oncol"},{"issue":"6","key":"2861_CR66","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","volume":"15","author":"TJ Price","year":"2014","unstructured":"Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappan S, Sidhu R (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15(6):569\u2013579. doi: 10.1016\/S1470-2045(14)70118-4","journal-title":"Lancet Oncol"},{"issue":"6","key":"2861_CR67","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1053\/j.gastro.2006.01.043","volume":"130","author":"J Andersson","year":"2006","unstructured":"Andersson J, Bumming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, Oden A, Gustavsson B, Kindblom LG, Nilsson B (2006) Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130(6):1573\u20131581. doi: 10.1053\/j.gastro.2006.01.043","journal-title":"Gastroenterology"},{"key":"2861_CR68","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1146\/annurev.pathmechdis.3.121806.151538","volume":"3","author":"CL Corless","year":"2008","unstructured":"Corless CL, Heinrich MC (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3:557\u2013586. doi: 10.1146\/annurev.pathmechdis.3.121806.151538","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"2861_CR69","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00280-013-2135-8","volume":"72","author":"S Patel","year":"2013","unstructured":"Patel S (2013) Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemother Pharmacol 72(2):277\u2013286. doi: 10.1007\/s00280-013-2135-8","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"2861_CR70","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23):4342\u20134349. doi: 10.1200\/JCO.2003.04.190","journal-title":"J Clin Oncol"},{"issue":"12","key":"2861_CR71","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"CL Corless","year":"2011","unstructured":"Corless CL, Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 11(12):865\u2013878. doi: 10.1038\/nrc3143","journal-title":"Nat Rev Cancer"},{"issue":"9544","key":"2861_CR72","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329\u20131338. doi: 10.1016\/S0140-6736(06)69446-4","journal-title":"Lancet"},{"issue":"9863","key":"2861_CR73","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schoffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, Investigators Gs (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295\u2013302. doi: 10.1016\/S0140-6736(12)61857-1","journal-title":"Lancet"},{"issue":"7","key":"2861_CR74","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/annonc\/mdr598","volume":"23","author":"P Reichardt","year":"2012","unstructured":"Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, McArthur GA, Yazji S, Hsu Y, Galetic I, Rutkowski P (2012) Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 23(7):1680\u20131687. doi: 10.1093\/annonc\/mdr598","journal-title":"Ann Oncol"},{"issue":"21","key":"2861_CR75","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","volume":"29","author":"J Guo","year":"2011","unstructured":"Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29(21):2904\u20132909. doi: 10.1200\/JCO.2010.33.9275","journal-title":"J Clin Oncol"},{"issue":"5","key":"2861_CR76","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-11-1987","volume":"18","author":"DR Minor","year":"2012","unstructured":"Minor DR, Kashani-Sabet M, Garrido M, O\u2019Day SJ, Hamid O, Bastian BC (2012) Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18(5):1457\u20131463. doi: 10.1158\/1078-0432.CCR-11-1987","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2861_CR77","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1007\/s10637-011-9763-9","volume":"30","author":"JH Cho","year":"2012","unstructured":"Cho JH, Kim KM, Kwon M, Kim JH, Lee J (2012) Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30(5):2008\u20132014. doi: 10.1007\/s10637-011-9763-9","journal-title":"Invest New Drugs"},{"issue":"12","key":"2861_CR78","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","volume":"14","author":"S Verstovsek","year":"2008","unstructured":"Verstovsek S, Tefferi A, Cortes J, O\u2019Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14(12):3906\u20133915. doi: 10.1158\/1078-0432.CCR-08-0366","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2861_CR79","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","volume":"20","author":"R Jeselsohn","year":"2014","unstructured":"Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gomez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA (2014) Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 20(7):1757\u20131767. doi: 10.1158\/1078-0432.CCR-13-2332","journal-title":"Clin Cancer Res"},{"issue":"4785","key":"2861_CR80","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235(4785):177\u2013182","journal-title":"Science"},{"key":"2861_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.02.002","author":"G Mustacchi","year":"2015","unstructured":"Mustacchi G, Biganzoli L, Pronzato P, Montemurro F, Dambrosio M, Minelli M, Molteni L, Scaltriti L (2015) HER2-positive metastatic breast cancer: a changing scenario. Crit Rev Oncol\/Hematol. doi: 10.1016\/j.critrevonc.2015.02.002","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"9737","key":"2861_CR82","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235\u2013244. doi: 10.1016\/S0140-6736(10)60892-6","journal-title":"Lancet"},{"issue":"2","key":"2861_CR83","first-page":"147","volume":"1","author":"MF Di Renzo","year":"1995","unstructured":"Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S et al (1995) Overexpression and amplification of the met\/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1(2):147\u2013154","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2861_CR84","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/sj.onc.1203455","volume":"19","author":"MF Di Renzo","year":"2000","unstructured":"Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19(12):1547\u20131555. doi: 10.1038\/sj.onc.1203455","journal-title":"Oncogene"},{"issue":"18","key":"2861_CR85","first-page":"5126","volume":"62","author":"EM Boon","year":"2002","unstructured":"Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST (2002) Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 62(18):5126\u20135128","journal-title":"Cancer Res"},{"issue":"5827","key":"2861_CR86","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039\u20131043. doi: 10.1126\/science.1141478","journal-title":"Science"},{"issue":"52","key":"2861_CR87","doi-asserted-by":"publisher","first-page":"20932","DOI":"10.1073\/pnas.0710370104","volume":"104","author":"J Bean","year":"2007","unstructured":"Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104(52):20932\u201320937. doi: 10.1073\/pnas.0710370104","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"2861_CR88","doi-asserted-by":"publisher","first-page":"10090","DOI":"10.1158\/0008-5472.CAN-10-0489","volume":"70","author":"F Shojaei","year":"2010","unstructured":"Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG (2010) HGF\/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 70(24):10090\u201310100. doi: 10.1158\/0008-5472.CAN-10-0489","journal-title":"Cancer Res"},{"issue":"25","key":"2861_CR89","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O\u2019Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385\u20132394. doi: 10.1056\/NEJMoa1214886","journal-title":"N Engl J Med"},{"issue":"11","key":"2861_CR90","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","volume":"12","author":"AT Shaw","year":"2011","unstructured":"Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11):1004\u20131012. doi: 10.1016\/S1470-2045(11)70232-7","journal-title":"Lancet Oncol"},{"key":"2861_CR91","doi-asserted-by":"crossref","unstructured":"Shaw AT, Mehra R, Kim D-W et al (2013) Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. In: ASCO meeting abstracts, vol 31, p 8010","DOI":"10.1200\/jco.2013.31.15_suppl.8010"},{"issue":"11","key":"2861_CR92","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1158\/1078-0432.CCR-12-3381","volume":"19","author":"MA Socinski","year":"2013","unstructured":"Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI (2013) A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 19(11):3068\u20133077. doi: 10.1158\/1078-0432.CCR-12-3381","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2861_CR93","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/0959-437X(94)90072-B","volume":"4","author":"I Greenwald","year":"1994","unstructured":"Greenwald I (1994) Structure\/function studies of lin-12\/Notch proteins. Curr Opin Genet Dev 4(4):556\u2013562","journal-title":"Curr Opin Genet Dev"},{"key":"2861_CR94","doi-asserted-by":"crossref","unstructured":"Rugo HS, Olopade O, DeMichele A, van \u2018t Veer L, Buxton MB, Hylton N, Yee D, Chien AJ, Wallace A, PI\u2019s I-SS, Lyandres J, Davis S, Sanil A, Berry D, Esserman L (2013) Veliparib\/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 TRIAL. In: 36th Annual San Antonio breast cancer symposium, Abstract S5-02","DOI":"10.1158\/0008-5472.SABCS13-S5-02"},{"issue":"8","key":"2861_CR95","doi-asserted-by":"publisher","first-page":"e105524","DOI":"10.1371\/journal.pone.0105524","volume":"9","author":"J Chang","year":"2014","unstructured":"Chang J, Liu X, Wang S, Zhang Z, Wu Z, Zhang X, Li J (2014) Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis. PLoS One 9(8):e105524. doi: 10.1371\/journal.pone.0105524","journal-title":"PLoS One"},{"issue":"1","key":"2861_CR96","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2014.07.083","volume":"135","author":"MA Powell","year":"2014","unstructured":"Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM (2014) A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group Study. Gynecol Oncol 135(1):38\u201343. doi: 10.1016\/j.ygyno.2014.07.083","journal-title":"Gynecol Oncol"},{"issue":"11","key":"2861_CR97","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-13-3006","volume":"20","author":"B Escudier","year":"2014","unstructured":"Escudier B, Grunwald V, Ravaud A, Ou YC, Castellano D, Lin CC, Gschwend JE, Harzstark A, Beall S, Pirotta N, Squires M, Shi M, Angevin E (2014) Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin Cancer Res 20(11):3012\u20133022. doi: 10.1158\/1078-0432.CCR-13-3006","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2861_CR98","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/jnci\/djs258","volume":"104","author":"D Yee","year":"2012","unstructured":"Yee D (2012) Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 104(13):975\u2013981. doi: 10.1093\/jnci\/djs258","journal-title":"J Natl Cancer Inst"},{"key":"2861_CR99","doi-asserted-by":"publisher","DOI":"10.1200\/EdBook_AM.2013.33.118","author":"AM Tsimberidou","year":"2013","unstructured":"Tsimberidou AM, Ringborg U, Schilsky RL (2013) Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book. doi: 10.1200\/EdBook_AM.2013.33.118","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"18","key":"2861_CR100","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1158\/1078-0432.CCR-14-0603","volume":"20","author":"AM Tsimberidou","year":"2014","unstructured":"Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D (2014) Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res 20(18):4827\u20134836. doi: 10.1158\/1078-0432.CCR-14-0603","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2861-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2861-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2861-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2861-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T09:36:12Z","timestamp":1692005772000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2861-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,21]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["2861"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2861-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,21]]},"assertion":[{"value":"10 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}